On November 11, 2021 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies London Healthcare Conference on November 16 and the Evercore ISI 4th Annual HealthCONx Conference on November 30 (Press release, Turning Point Therapeutics, NOV 11, 2021, View Source [SID1234595277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Countouriotis is scheduled to present a company overview in London at 7:20 a.m. ET (12:20 p.m. GMT) on November 16 and participate in a virtual fireside chat at 1 p.m. ET on November 30. Both sessions will be accessible via webcast through the Investors page of www.tptherapeutics.com.